5th Annual Drug Development Congress 2013

Oxford Global Conferences are proud to present the 5th Annual Drug Development Congress, taking place on the 10th & 11th June in Geneva.

It is estimated that the average drug costs the world’s leading pharmaceutical companies at least $4 billion to develop. Amid fears that the current large pharma model is not working, this event focuses on attempts to break down discovery and development boundaries and promote knowledge share between therapy areas.

On Day One, our expert speakers will discuss key areas for improvement in drug development, including translational modelling, safety & efficacy testing and reducing timelines for biopharmaceutical pipelines. Topics will include assay development, pharmacokinetic challenges and updates on the latest NGS applications.

Day Two will cover the latest methods to improve decision making in drug development; from advances in biomarker technology, to the integration of safety studies earlier in the pipeline. Our expert speakers will also present collaboration case studies, discussing both external and internal attempts to harness complimentary skills and reduce late stage failure.

To maintain the extensive networking opportunities enjoyed by last year’s delegates, the development congress will once again be co-located with our discovery summit. The 14th Annual Drug Discovery Leaders’ Summit has a long-held association with the leaders in medicinal chemistry and drug design. This year’s event will focus on innovation. Experts will discuss how new developments in screening, assay development, structure-activity analysis and anti-target effect prediction will influence the success of discovery portfolios.

For more information on the agenda or registration enquiries please email: d.meredith@oxfordglobal.co.uk